Abstract: A chewable pharmaceutical composition comprising phenylephrine, artificial sweetener, and a substantially aldehyde-free matrix is provided. The composition has phenylephrine stability suitable for a typical commercial product with a two year shelf life. A method of manufacture of the composition and a method of use are also provided.
Type:
Grant
Filed:
July 25, 2006
Date of Patent:
April 14, 2015
Assignee:
Wyeth
Inventors:
Josephine Fubara, Mark Mabry, Aaron Lewis Durr, Angela Taylor, Amanda Alley, David H. Giamalva, Manish Agrawal
Abstract: The present invention is directed to a nonaqueous pressure-sensitive adhesive that may be used in medicinal tape preparations for percutaneous absorption. The adhesive may comprise a copolymer obtained by copolymerization of a (meth)acrylic monomer having an acetoacetyl group in the molecule and one or more monomers from among other (meth)acrylic monomers without acetoacetyl groups and copolymerizable vinyl monomers, in a nonaqueous solvent. Suitable (meth)acrylic monomers having an acetoacetyl group in the molecule are acetoacetoxyalkyl methacrylates, and especially 2-acetoacetoxyethyl methacrylate. The pressure-sensitive adhesive of the invention uses no polyamine derivatives, isocyanate compounds, polyvalent metal chelate compounds, etc., as crosslinking agents, and therefore toxicity is not a concern and skin is not irritated. A medicinal tape preparation for percutaneous absorption of the invention has superior adhesive strength and cohesive strength, and is highly safe with low skin irritation.
Abstract: Sunless tanning compositions with adjuvants comprising sulfur comprising moieties are described. The compositions comprise an adjuvant with a +6 oxidation state sulfur moiety and results in excellent artificial tanning results within a consumer acceptable time.
Type:
Grant
Filed:
November 6, 2012
Date of Patent:
February 24, 2015
Assignee:
Conopco, Inc.
Inventors:
Pravin Shah, Joseph Oreste Carnali, Qiang Qiu
Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.
Abstract: One aspect of the invention relates to new materials for storing, protecting, selectively releasing, and applying active ingredients (e.g. pharmaceuticals and other chemicals). In certain embodiments, the invention provides materials impregnated with water-soluble polymer particles which contain active ingredients which may be selectively released and dispensed in response to contact with water or another liquid.
Abstract: One aspect of the present invention relates to bronchoscopic lung volume reduction using solutions of biopolymers that can be polymerized in situ with a crosslinker and a polymeric additive which accelerates the cross-linking reaction. In certain embodiments, the biopolymer solutions can be in the form of a foam or gel. The biopolymer compositions disclosed herein may also be used for indications other than lung volume reduction, such as sealing fistulas or performing emergency tamponade of vessels.
Abstract: Topical mixtures with ranges of permeability which promote dermal healing, wound stage arrest, skin cooling, and patient comfort through pH adjustment, therapeutic ingredient carriage, water and oxygen delivery, with superior aesthetics and ease of cleaning features.
Abstract: The invention relates to pharmaceutical agents containing a particulate inorganic matrix having a diameter of from 0.1 nm to 100 ?m, preferably 1 nm to 10 ?m, particularly preferably 1 nm to 1 ?m, such as, for example, topaz, (Al2F2)[SiO4], and chiolite, Na[Al3F4], preferably wavellite, Al3(PO4)2(OH,F)2, calcium carbonate, CaCO3, maghemite, ?-Fe2O3, particularly preferably zeolites, gen. formula Mn[(AlO2)x(SiO2)y] (M=metal, e.g.
Abstract: A polymer coating for medical devices based on a polyolefin derivative. A variety of polymers are described to make coatings for medical devices, particularly, for drug delivery stents. The polymers include homo-, co-, and terpolymers having at least one olefin-derived unit and at least one unit derived from vinyl alcohol, allyl alcohol and derivatives thereof.
Abstract: A method for producing a patch comprising a support layer and an adhesive agent layer arranged on at least one surface of the support layer, the method comprising: a step A of obtaining an adhesive agent layer composition comprising oxybutynin hydrochloride as a drug, an acrylic-based polymer and/or a rubber-based polymer as an adhesive base agent, liquid paraffin, a sterol, an organic acid, and a tackifier; a step B of heating the adhesive agent layer composition at a temperature in a range from 55 to 70° C. for 1 to 24 hours; and a step C of cooling the heated adhesive agent layer composition to a temperature lower than room temperature at an average rate of temperature drop of 1 to 20° C./hour, thereby obtaining the adhesive agent layer comprising the drug at a supersaturated concentration in a dissolved form.
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Abstract: Bioswellable sutures are provided in the form of absorbable, compliant monofilaments of an amphiphilic copolyester, an absorbable multifilament braid, a non-absorbable monofilament with swellable outer layer, a non-absorbable multifilament braid with an absorbable monofilament core of an amphiphilic copolymer, and a non-absorbable, multifilament braid molecularly integrated with an outer sheath that is highly hydrophilic.
Type:
Grant
Filed:
June 14, 2006
Date of Patent:
October 14, 2014
Assignee:
Poly-Med, Inc.
Inventors:
Shalaby W. Shalaby, James M. Lindsey, III
Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising a pharmaceutically active amphetamine salt covered with an immediate-release coating and a pharmaceutically active amphetamine salt covered with an enteric coating wherein the immediate release coating and the enteric coating provide for multiple pulsed dose delivery of the pharmaceutically active amphetamine salt. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.
Type:
Grant
Filed:
May 12, 2006
Date of Patent:
September 30, 2014
Assignee:
Shire LLC
Inventors:
Amir Shojaei, Stephanie Read, Richard A. Couch, Paul Hodgkins
Abstract: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average Tmax within the range of about 2 to about 8 hours with an active ingredient load within the range of about 2.5 to about 150 mg. The formulation allows for dose-proportional compositions for once daily or b.i.d. dosing, while maintaining a steady average range of Tmax.
Type:
Grant
Filed:
June 8, 2011
Date of Patent:
September 16, 2014
Assignee:
Forest Laboratories Holdings Limited
Inventors:
Yan Yang, Rajiv Janjikhel, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Erhard Seiller, Bernhard Hauptmeier
Abstract: A composition and method for imparting a sunless tan to skin is described. The composition and method make use of a sunless tanning agent like dihydroxyacetone in combination with an adjuvant which is a pyranone, furanone or a mixture thereof.
Type:
Grant
Filed:
December 24, 2009
Date of Patent:
August 26, 2014
Assignee:
Conopco, Inc.
Inventors:
Joseph Oreste Carnali, Weimin Peng, Xiaoxia Yang
Abstract: The invention relates to a biocompatible polymer having general formula (I) AaXxYy, wherein: A denotes a monomer; X denotes an RCOOR? group; Y denotes an O or N-sulphonate group which is fixed to A and which has either formula —ROS03R? or —RNS03R? in which R denotes an optionally branched and/or unsaturated aliphatic hydrocarbon chain which can contain one or more aromatic rings and R? denotes a hydrogen atom or a cation; a denotes the number of monomers; x denotes the rate of substitution of the A monomers by the X groups; and y denotes the rate of substitution of the A monomers by the Y groups. More specifically, the invention relates to the use of said biocompatible polymers for the preparation of a pharmaceutical, dermatological or cosmetic composition or a medical device, which are intended to prevent, relieve and/or treat discomfort, distress, itches, irritations and/or pain and/or to protect tissues against same.
Abstract: Implantable devices formed of or coated with a material that includes an amorphous poly(D,L-lactide) formed of a starting material such as meso-D,L-lactide are provided. The implantable device can be used for the treatment, mitigation, prevention, or inhibition of a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
Type:
Grant
Filed:
April 29, 2005
Date of Patent:
July 15, 2014
Assignee:
Advanced Cardiovascular Systems, Inc.
Inventors:
Stephen D. Pacetti, Syed Faiyaz Ahmed Hossainy, David C. Gale
Abstract: This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.
Type:
Grant
Filed:
February 24, 2012
Date of Patent:
July 1, 2014
Assignees:
STC.UNM, University of Kansas
Inventors:
Angela Wandinger-Ness, Larry Sklar, Jacob Agola, Zurab Surviladze, Jeffrey Aubé, Jennifer Golden, Chad E. Schroeder, Denise S. Simpson